Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Escitalopram Oxalate

FDA-approved product (tablet, oral), marketed as Escitalopram, Escitalopram Oxalate, Lexapro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Escitalopram Oxalate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Generalized anxiety disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Escitalopram Oxalate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Escitalopram Oxalate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Beta-CIT-SPECT and Neurophysiology in Depression

    NCT00145132 · start 2005-06

    Registered record
    Registry ID
    NCT00145132
    Conditions
    Depression
    Interventions
    β-CIT-SPECT, Neurophysiology
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    2009-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    Interventionβ-CIT-SPECT, Neurophysiology
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

    NCT00235508 · start 2005-06

    Registered record
    Registry ID
    NCT00235508
    Conditions
    Insomnia; Generalized Anxiety Disorder
    Interventions
    Eszopiclone (Lunesta)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    2006-04
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Generalized Anxiety Disorder
    InterventionEszopiclone (Lunesta)
    PhasePhase 4
    Registry statusCompleted

  • The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis

    NCT00151294 · start 2004-11

    Registered record
    Registry ID
    NCT00151294
    Conditions
    Depression; Multiple Sclerosis
    Interventions
    escitalopram oxalate antidepressant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-11
    Completion
    2006-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Multiple Sclerosis
    Interventionescitalopram oxalate antidepressant
    PhasePhase 4
    Registry statusTerminated

  • The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram

    NCT00179257 · start 2004-06

    Registered record
    Registry ID
    NCT00179257
    Conditions
    Major Depressive Disorder
    Interventions
    sertraline (Zoloft)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    Interventionsertraline (Zoloft)
    PhasePhase 3
    Registry statusCompleted

  • Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder

    NCT01024140 · start 2003-02

    Registered record
    Registry ID
    NCT01024140
    Conditions
    Chronic Posttraumatic Stress Disorder
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-02
    Completion
    2004-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Posttraumatic Stress Disorder
    InterventionEscitalopram
    PhaseNot applicable
    Registry statusCompleted